Sign Out
Zeffix is indicated for the treatment of chronic hepatitis B in adults with compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see Pharmacology: Pharmacodynamics under Actions).
Treatment of chronic hepatitis B in adults with decompensated liver disease in combination with a second agent without cross-resistance to lamivudine (see Dosage & Administration).
